In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dynogen licenses Phase II GI compound from Mitsubishi

Executive Summary

Dynogen Pharmaceuticals (in-licenses neuroscience-based compounds to apply to genitourinoary and gastrointestinal indications) has acquired exclusive rights in most of the world to develop Mitsubishi Pharma's pumosetrag, which showed good safety and pharmacokinetic profiles in Phase II.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies